Vanguard Group Inc. Has $14.43 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Vanguard Group Inc. lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERNFree Report) by 0.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,199,006 shares of the company’s stock after acquiring an additional 11,535 shares during the quarter. Vanguard Group Inc.’s holdings in Terns Pharmaceuticals were worth $14,425,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of TERN. Bleakley Financial Group LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $68,000. Simplicity Solutions LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $68,000. Russell Investments Group Ltd. acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $1,803,000. AJOVista LLC acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $58,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $106,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

Insider Transactions at Terns Pharmaceuticals

In other news, Director Jill M. Quigley sold 6,143 shares of Terns Pharmaceuticals stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $7.68, for a total value of $47,178.24. Following the completion of the transaction, the director now directly owns 23,857 shares of the company’s stock, valued at approximately $183,221.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Carl L. Gordon sold 50,976 shares of Terns Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $10.00, for a total value of $509,760.00. Following the completion of the transaction, the director now directly owns 756,258 shares of the company’s stock, valued at approximately $7,562,580. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jill M. Quigley sold 6,143 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $7.68, for a total value of $47,178.24. Following the completion of the sale, the director now directly owns 23,857 shares of the company’s stock, valued at $183,221.76. The disclosure for this sale can be found here. Corporate insiders own 15.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. BMO Capital Markets reissued an “outperform” rating and set a $19.00 price objective on shares of Terns Pharmaceuticals in a report on Tuesday, August 6th. HC Wainwright reissued a “neutral” rating and set a $5.50 price objective on shares of Terns Pharmaceuticals in a report on Tuesday, May 14th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $15.00 target price on shares of Terns Pharmaceuticals in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Terns Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Get Our Latest Analysis on Terns Pharmaceuticals

Terns Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:TERN opened at $6.57 on Tuesday. Terns Pharmaceuticals, Inc. has a 12-month low of $3.26 and a 12-month high of $10.03. The business has a fifty day simple moving average of $7.64 and a 200 day simple moving average of $6.70.

Terns Pharmaceuticals (NASDAQ:TERNGet Free Report) last announced its earnings results on Monday, August 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.04. On average, analysts forecast that Terns Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Terns Pharmaceuticals Company Profile

(Free Report)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Further Reading

Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERNFree Report).

Institutional Ownership by Quarter for Terns Pharmaceuticals (NASDAQ:TERN)

Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.